Placeholder Banner

BIO Statement on New Proposal for Lowering Out-of-Pocket Costs for Medicines

January 31, 2019
Media Contact
Brian Newell
202.312.9268

Washington, DC (January 31, 2019) – BIO’s President and CEO Jim Greenwood issued the following statement today after the Trump administration released a proposed rule that would alter safe harbor policies under the federal anti-kickback statute:

“BIO strongly supports the goal of this proposed rule to lower out-of-pocket costs for consumers. Every year innovative drugmakers provide tens of billions of dollars in rebates to help expand affordable access to prescription medicines. But far too often these rebates are not passed along to patients and are instead used to pad the profits of middlemen. The current system creates perverse incentives that are driving the affordability crisis many patients face today.

“We firmly believe that the rebates drugmakers provide insurers and other middlemen should be used to lower what patients pay out of pocket for prescription medicines. While we intend to carefully review the details of this proposed rule, we are encouraged the administration is moving forward with market-based reforms that are aimed at lowering out-of-pocket costs for prescription drugs. We urge the administration to adopt a final rule that leads to a fairer system and helps provide more patients affordable access to the medicines they need.”

Discover More
Washington, D.C. (November 21, 2019) — Speaker Nancy Pelosi’s Lower Drug Costs Now Act of 2019, H.R.3, could result in at least 56 fewer new medicines for patients over 10 years, according to a new analysis from economic…
Following the introduction of the Trump administration’s drug importation proposal, BIO’s President and CEO Jim Greenwood issued the following statement: “There is simply no way to adopt an importation scheme that doesn’t jeopardize the health and…
“What has set the U.S. biotech sector apart has been thoughtful, bipartisan public policy approaches that create a favorable climate in which to undertake the lengthy and risky job of investing in and developing the next biotech breakthroughs.”